Form 4: Cytosorbents Director Michael G. Bator Reports Stock Option Grant

Director Michael G. Bator reports the acquisition of 44,000 stock options in Cytosorbents Corp.

Summary

• Michael G. Bator, a director of Cytosorbents Corp, filed a Form 4 on April 4, 2024, reporting a transaction.
• On April 2, 2024, Bator acquired 44,000 stock options with an exercise price of $0.955.
• These options were granted under the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan.
• The options vest in four equal quarterly installments over one year, contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard stock option grant to a director, which is a common practice.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Key Dates